EXCLUSIVE: Adaptimmune Therapeutics CEO Adrian Rawcliffe Tells Benzinga Co. Will Continue To Work Toward Bringing First Allogeneic Cell Therapy, A MAGE-A4 Targeted Product, To The Clinic